WHAT IS CLAIMED IS:

1. A compound of Formula I:



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

x is 1, 2 or 3;

R represents from 0 to 4 substituents independently chosen from halogen, hydroxy, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, cyano, amino, nitro, -COOH, carboxamide, optionally substituted mono- and di-alkyl amino, optionally substituted haloalkyl, and optionally substituted haloalkoxy;

R^1 is selected from alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, aryl, heteroaryl, (aryl)alkyl, (heteroaryl)alkyl, and indanyl, each of which is optionally substituted;

R^2, R^3 and each occurrence of R^4 are independently selected from hydrogen, halogen, optionally substituted alkyl, and optionally substituted alkoxy;

R^5 and R^6 are independently selected from

(i) hydrogen, halogen, hydroxy, amino, and cyano; and

(ii) alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, and mono- and di-(alkyl)amino, each of which is optionally substituted;

R^7 is: (a) (i) hydrogen; or (ii) alkyl, alkenyl, alkynyl, alkoxy or arylalkyl, each of which is optionally substituted; and

Ar^1 is:

(i) phenyl, naphthyl, biphenyl, or heterocycle, each of which is optionally substituted; or

(ii) optionally substituted phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having from 5 to 7 ring atoms, with 0, 1, or 2 ring atoms independently chosen from N, O and S, and with remaining ring atoms being carbon;

or

(b) taken together with Ar^1 and the carbon atom to which R^7 and Ar^1 are attached to form an optionally substituted group of the formula:



wherein p is an integer from 1 to about 3; and

Ar^2 is (i) optionally substituted aryl or (ii) optionally substituted heteroaryl having 5 to 7 ring atoms and from 1 to 3 ring heteroatoms independently selected from N, O and S.

2. A compound or salt according to Claim 1, wherein:

x is 1;

R represents from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, -COOH, carboxamide, C_1-C_6alkoxy, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy;

R^1 is selected from (aryl)C_0-C_6alkyl, (heteroaryl)C_0-C_6alkyl, and indanyl, each of which is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, -COOH, carboxamide, C_1-C_6alkoxy, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy;

R^2, R^3, and each occurrence of R^4 are independently selected from hydrogen, halogen, C_1-C_6alkyl, and C_1-C_6alkoxy;

R^5 and R^6 are independently selected from hydrogen, halogen, cyano, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, hydroxy, amino, and mono- and di-(C_1-C_6alkyl)amino;

and either:

(a) R^7 is (i) hydrogen; or (ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkynyl, C_1-C_6alkoxy or (aryl)C_1-C_6alkyl, each of which is optionally substituted; and

Ar^1 is (i) phenyl; (ii) naphthyl; (iii) biphenyl; (iv) a heterocyclic group having 1 or 2 rings, 3 to 8 atoms in each ring and in at least one ring from 1 to 3 heteroatoms independently selected from N, O and S; or (v) phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having from 5 to 7 ring atoms, with 0, 1 or 2 ring atoms chosen from N, O and S, and with remaining ring atoms being carbon;

wherein each of (i), (ii), (iii), (iv) and (v) is substituted with from 0 to 4 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, C_1-C_6alkoxy, C_1-

C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6alkoxycarbonyl, -COOH, carboxamide, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy; or

(b) R^7 is taken together with Ar^1 and the carbon atom to which R^7 and Ar^1 are attached to form a group of the formula:



, substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, -COOH, carboxamide, C_1-C_6 alkoxy, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy, wherein p is an integer from 1 to about 3; and

Ar^2 is aryl or heteroaryl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, -COOH, C_1-C_6alkoxy, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6alkoxycarbonyl, carboxamide, mono- and di-(C_1-C_6alkyl)carboxamide, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy.

3. A compound or salt according to Claim 1, wherein R^1 is indanyl, substituted with 0, 1, or 2 substituents independently selected from halogen, hydroxy, C_1-C_2alkoxy, C_1-C_2alkyl, haloC_1-C_2alkyl, and haloC_1-C_2alkoxy.

4. A compound or salt according to Claim 1, wherein R^1 is phenyl(C_0-C_4alkyl), pyridyl(C_0-C_4alkyl), C_0-C_4alkyl, or indolyl(C_0-C_4alkyl), each of which is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, C_1-C_2alkoxy, C_1-C_2alkyl, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

5. A compound or salt according to Claim 1, wherein R^1 is phenyl(C_0-C_2alkyl) substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, C_1-C_2alkoxy, C_1-C_2alkyl, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

6. A compound or salt according to Claim 1, wherein R^2 and R^3 are hydrogen.

7. A compound or salt according to Claim 1, wherein each R^4 is independently hydrogen or C_1-C_6alkyl.

8. A compound or salt according to Claim 1, wherein R^5 and R^6 are independently selected from hydrogen, halogen, C_1-C_2alkyl and C_1-C_2alkoxy.

9. A compound or salt according to Claim 1, wherein R represents 0, 1, or 2 substituents independently selected from C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, fluoro, and chloro.

10. A compound or salt according to Claim 1, wherein

R represents 0, 1, or 2 substituents independently selected from hydrogen, methyl, ethyl, methoxy, trifluoromethyl, trifluoromethoxy, fluoro, and chloro;

R^2, R^3, and R^6 are hydrogen; and

R^5, R^7, and each R^4 are independently selected from hydrogen, methyl, and ethyl.

11. A compound or salt according to Claim 1, of Formula II



Formula II

wherein:

R represents from 0 to 4 substituents independently chosen from fluoro, chloro, hydroxy, optionally substituted C_1-C_6alkoxy and optionally substituted C_1-C_6alkyl;

R^4 is hydrogen, optionally substituted C_1-C_6alkyl, C_1-C_6haloalkyl, fluoro, or chloro;

R^5 and R^6 are independently selected from hydrogen, fluoro, chloro, optionally substituted C_1-C_6alkyl, optionally substituted C_1-C_6alkoxy, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy; and

R^7 is hydrogen or C_1-C_6 alkyl.

12. A compound or salt according to Claim 11, wherein

R represents from 0 to 4 substituents independently chosen from fluoro, chloro, hydroxy, C_1-C_6alkoxy, and C_1-C_6alkyl;

R^1 is selected from C_3-C_7cycloalkyl, (C_3-C_7cycloalkyl)C_1-C_4alkyl, (heteroaryl)C_0-C_4alkyl, (aryl)C_0-C_4alkyl, and indanyl, each of which is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, C_1-C_6alkoxy, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, -COOH, carboxamide, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy;

R^4 is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, fluoro, or chloro;

R^5 and R^6 are independently selected from hydrogen, fluoro, chloro, C_1-C_6alkyl, C_1-C_6alkoxy, haloC_1-C_6alkyl, and C_1-C_6haloalkoxy; and

R^7 is hydrogen or C_1-C_6 alkyl.

13. A compound or salt according to Claim 11 or 12, wherein

Ar^1 is:

(i) phenyl substituted with from 0 to 4 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, -COOH, carboxamide, C_1-C_3alkoxy, C_1-C_3alkyl, C_1-C_2haloalkyl, C_1-C_2alkoxycarbonyl, mono- and di-(C_1-C_2alkyl)amino, and C_1-C_2haloalkoxy;

(ii) naphthyl;

(iii) heterocyclic groups having 1 or 2 rings, 3 to 8 atoms in each ring and in at least one ring from 1 to 3 heteroatoms independently selected from N, O and S;

(iv) biphenyl, wherein each phenyl group is substituted with 0 to 2 groups independently selected from halogen, C_1-C_2alkyl, and C_1-C_2alkoxy; or

(v) phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having from 5 to 7 ring atoms, with 0, 1, or 2 ring atoms independently chosen from N, O and S, and with remaining ring atoms being carbon;

wherein each of (ii), (iii), (iv) and (v) is substituted with from 0 to 4 substituents independently selected from halogen, hydroxy, C_1-C_2alkyl, C_1-C_2alkoxy, C_1-C_2haloalkyl, and haloC_1-C_2alkoxy.

14. A compound or salt according to Claim 13, wherein Ar^2 is phenyl or heteroaryl having about 5 to 7 ring atoms and between 1 and 3 ring heteroatoms independently selected from N, O and S, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, -COOH, C_1-C_3alkoxy, C_1-C_3alkyl, carboxamide, dimethylcarboxamide, mono- and di-(C_1-C_2alkyl)amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

15. A compound or salt according to Claim 11, wherein Ar^2 is phenyl or heteroaryl having about 5 to 7 ring atoms and between 1 and 3 ring heteroatoms independently selected from N, O and S, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, -COOH, C_1-C_3alkoxy, C_1-C_3alkyl, carboxamide, dimethylcarboxamide, mono- and di-(C_1-C_2alkyl)amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

16. A compound or salt according to claim 12, wherein:

R represents from 0 to 2 substituents independently chosen from fluoro, chloro, hydroxy, methoxy, ethoxy, methyl, and ethyl;

R^1 is 1-indanyl or 2-indanyl, each of which is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, C_1-C_6alkoxy, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, -COOH, carboxamide, mono- and di-(C_1-C_6alkyl) amino, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy;

R^7 is hydrogen, methyl or ethyl;

Ar_1 is

(i) phenyl substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, -COOH, carboxamide, C_1-C_3alkoxy, C_1-C_3alkyl, C_1-C_2alkoxycarbonyl, mono- and di-(C_1-C_2alkyl)amino, haloC_1-C_2alkyl, and haloC_1-C_2alkoxy;

(ii) naphthyl;

(iii) heterocyclic groups having 1 or 2 rings, 3 to 8 atoms in each ring, and in at least one ring from 1 to 3 heteroatoms independently selected from N, O and S;

(iv) biphenyl; or

(v) phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having from 5 to 7 ring atoms, with 0, 1, or 2 ring atoms independently chosen from N, O and S, and with remaining ring atoms being carbon;

wherein each of (ii), (iii), (iv) and (v) is substituted with from 0 to about 4 substituents independently selected from halogen, hydroxy, C_1-C_2alkyl, C_1-C_2alkoxy, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy; and

Ar^2 is phenyl, pyridyl, thiazolyl, pyrimidyl, pyridizinyl, imidazolyl, oxazolyl, isoxazolyl and triazolyl, each of which is substituted with from 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, -COOH, C_1-C_3alkoxy, C_1-C_3alkyl, carboxamide, dimethylcarboxamide, mono- and di-(C_1-C_2alkyl)amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

17. A compound or salt according to claim 16, wherein

R represents from 0 to 2 substituents independently chosen from fluoro, chloro, hydroxy, methoxy, ethoxy, methyl and ethyl;

R^1 is 2-indanyl, substituted with 0, 1, or 2 substituents independently selected from fluoro, chloro, hydroxy, methyl, ethyl, methoxy, ethoxy, mono-, di- and tri-fluoromethyl, and mono-, di-, and tri-fluoromethoxy;

R^4 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, mono-, di-, or tri-fluoromethyl, or mono-, di- or tri-fluoromethoxy;

R^5 and R^6 are independently selected from hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy, mono-, di- and tri-fluoromethyl, and mono-, di-, and tri-fluoromethoxy;

Ar^1 is:

(i) phenyl, substituted with from 0 to 3 substituents independently selected from fluoro, chloro, bromo, hydroxy, methyl, methoxy, ethyl, ethoxy, mono-, di- and tri-fluoromethyl, and mono-, di-, and tri-fluoromethoxy; or

(ii) naphthyl, substituted with from 0 to 3 substituents independently selected from fluoro, chloro, hydroxy, methyl, ethyl, methoxy, and ethoxy; and

Ar^2 is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl or 1,3-thiazol-2-yl, each of which is substituted with from 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, -COOH, C_1-C_3alkoxy, C_1-C_3alkyl, carboxamide,

dimethylcarboxamide, mono- and di-(C_1-C_2alkyl)amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

18. A compound or salt according to Claim 12, wherein:

R represents from 0 to 2 substituents independently chosen from fluoro, chloro, hydroxy, methoxy, ethoxy, methyl, and ethyl;

R^1 is phenyl(C_0-C_2alkyl), substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cyano, amino, nitro, -COOH, carboxamide, mono- and di-(C_1-C_6alkyl) amino, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy;

R^7 is hydrogen, methyl, or ethyl;

Ar_1 is:

(i) phenyl substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, -COOH, carboxamide, C_1-C_3alkoxy, C_1-C_3alkyl, C_1-C_2alkoxycarbonyl, mono- and di-(C_1-C_2alkyl)amino, C_1-C_2haloalkyl, and C_1-C_2haloC_1-C_2alkoxy;

(ii) naphthyl;

(iii) a heterocyclic group having 1 or 2 rings, 3 to 8 atoms in each ring, and in at least one ring from 1 to 3 heteroatoms independently selected from N, O and S;

(iv) biphenyl; or

(v) phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having from 5 to 7 ring atoms, with 0, 1 or 2 ring atoms independently chosen from N, O and S, and with remaining ring atoms being carbon;

wherein each of (ii), (iii), (iv) and (v) is substituted with from 0 to about 4 substituents independently selected from halogen, hydroxy, C_1-C_2alkyl, C_1-C_2alkoxy, haloC_1-C_6alkyl, and haloC_1-C_2alkoxy; and

Ar^2 is phenyl, pyridyl, thiazolyl, pyrimidyl, pyridizinyl, imidazolyl, oxazolyl, isoxazolyl or triazolyl, each of which is substituted with from 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, -COOH, C_1-C_3alkoxy, C_1-C_3alkyl, carboxamide, dimethylcarboxamide, mono- and di-(C_1-C_2alkyl)amino, haloC_1-C_2alkyl and haloC_1-C_2alkoxy.

19. A compound or salt according to Claim 18, wherein R^1 is phenyl(C_0-C_1alkyl), substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, C_1-C_4alkoxy, C_1-C_4alkyl, -COOH, carboxamide, mono- and di-(C_1-C_4alkyl) amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

20. A compound or salt according to Claim 1, of Formula III



Formula III

wherein:

R represents from 0 to 4 substituents independently chosen from fluoro, chloro, hydroxy, C_1-C_6alkoxy, and C_1-C_6alkyl;

R^4 is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, fluoro, or chloro;

R^8 represents from 0 to 4 substituents independently chosen from C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, fluoro, and chloro;

R^5 and R^6 are independently selected from hydrogen, fluoro, chloro, C_1-C_6alkyl, optionally substituted C_1-C_6alkoxy, and haloC_1-C_6alkyl;

R^7 is hydrogen or C_1-C_6alkyl;

R^9 represents from 0 to 5 substituents independently chosen from halogen, hydroxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy; and

Ar^2 is (i) phenyl or (ii) heteroaryl having 5 to 7 ring atoms and from 1 to 3 ring heteroatoms independently selected from N, O and S, wherein each of (i) and (ii) is optionally substituted with from 1 to 5 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, -COOH, carboxamide, dimethylcarboxamide, C_1-C_3alkoxy, C_1-C_3alkyl, mono- and di-(C_1-C_2alkyl)amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

21. A compound or salt according to Claim 1, of Formula IV



Formula IV

wherein:

R represents from 0 to 4 substituents independently chosen from fluoro, chloro, hydroxy, C_1-C_6alkoxy, and C_1-C_6alkyl;

R^4 is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, fluoro, or chloro;

R^8 represents from 0 to 4 substituents independently chosen from C_1-C_6alkyl, C_1-C_6haloalkyl, fluoro, and chloro;

R^5 and R^6 are independently selected from hydrogen, fluoro, chloro, C_1-C_6alkyl, optionally substituted C_1-C_6alkoxy, and C_1-C_6haloalkyl;

R^7 is hydrogen or C_1-C_6alkyl;

R^{10} represents from 0 to 5 substituents independently chosen from fluoro, chloro, bromo, iodo, hydroxy, nitro, cyano, -COOH, carboxamide, dimethylcarboxamide, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy; and

Ar_1 is:

(i) phenyl substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, -COOH, carboxamide, C_1-C_3alkoxy, C_1-C_3alkyl, C_1-C_2haloalkyl, C_1-C_2alkoxycarbonyl, mono- and di-(C_1-C_2alkyl)amino, and C_1-C_2haloalkoxy;

(ii) naphthyl;

(iii) heterocyclic groups having 1 or 2 rings, 3 to 8 atoms in each ring and in at least one ring from 1 to 3 heteroatoms independently selected from N, O and S;

(iv) biphenyl; or

(v) phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having from 5 to 7 ring atoms, with 0, 1, or 2 ring atoms independently chosen from N, O and S, and with remaining ring atoms being carbon;

wherein each of (ii), (iii), (iv) and (v) is substituted with from 0 to 4 substituents independently selected from halogen, hydroxy, C_1-C_2alkyl, C_1-C_2alkoxy, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

22. A compound or salt according to Claim 21, of Formula V



Formula V

wherein:

R represents from 0 to 4 substituents independently chosen from fluoro, chloro, hydroxy, methyl, ethyl, methoxy, or ethoxy;

R^4 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, mono-, di- or tri-fluoromethyl, or mono-, di-, or tri-fluoromethoxy;

R^5 and R^6 are independently chosen from hydrogen, fluoro, chloro, methyl, methoxy, mono-, di- and tri-fluoromethyl, and mono-, di- and tri-fluoromethoxy;

R^7 is hydrogen, methyl, or ethyl; and

R^{10} is hydrogen, fluoro, chloro, bromo, hydroxy, methyl, ethyl, methoxy, or ethoxy.

23. A compound of the Formula VI



Formula VI

or a pharmaceutically acceptable salt thereof, wherein:

R is hydrogen, fluoro, chloro, hydroxy, methyl, or methoxy;

R^4 is hydrogen, methyl, or ethyl;

R^8 is hydrogen, fluoro, chloro, methyl, or methoxy;

R^9 is fluoro, chloro, methyl, ethyl, methoxy, ethoxy, mono-, di- or tri-fluoromethyl, or mono-, di-, or tri-fluoromethoxy;

R^{9A} represents 0, 1, or 2 substituents independently selected from hydrogen, fluoro, chloro, methyl, methoxy, mono-, di- and tri-fluoromethyl, and mono-, di-, and tri-fluoromethoxy;

R^{10} is hydrogen, fluoro, chloro, hydroxy, methyl, methoxy, mono-, di-, or tri-fluoromethyl, or mono-, di-, or tri-fluoromethoxy; and

R^{10A} represents from 0 to 3 substituents independently selected from hydrogen, fluoro, chloro, hydroxy, methyl, methoxy, mono-, di- and tri-fluoromethyl, and mono-, di-, and tri-fluoromethoxy.

24. A compound or salt according to claim 23, of Formula VII



Formula VII

25. A compound of Formula VIII



Formula VIII

or a pharmaceutically acceptable salt thereof, wherein:

A is N or CR^{10};

B is N or CR^{10A}, wherein at least one of A and B is not N;

R is hydrogen, fluoro, chloro, hydroxy, methyl, or methoxy;

R^4 is hydrogen, methyl, or ethyl;

R^8 is hydrogen, fluoro, chloro, methyl or methoxy;

R^{10}, if present, is hydrogen, fluoro, chloro, hydroxy, nitro, cyano, methyl, methoxy, mono-, di- or tri-fluoromethyl, or mono-, di-, or tri-fluoromethoxy;

R^{10A}, if present, is hydrogen, fluoro, chloro, hydroxy, nitro, cyano, methyl, methoxy, mono-, di- or tri-fluoromethyl, or mono-, di-, or tri-fluoromethoxy; and

R^{10B} represents from 0 to 3 substituents independently selected from fluoro, chloro, hydroxy, nitro, cyano, methyl, methoxy, mono-, di- and tri-fluoromethyl, and mono-, di-, and tri-fluoromethoxy.

26. A compound or salt according to Claim 25, of Formula IX



Formula IX

wherein:

R is hydrogen, fluoro, chloro, hydroxy, methyl or methoxy;

R^4 is hydrogen, methyl, or ethyl;

R^8 is hydrogen, fluoro, chloro, methyl or methoxy; and

R^{10} is hydrogen, fluoro, chloro, hydroxy, methyl, methoxy, mono-, di- or tri-fluoromethyl, or mono-,

di-, or tri-fluoromethoxy.

27. A compound according to Claim 1, of Formula X



Formula X

or a pharmaceutically acceptable salt thereof, wherein:

R is hydrogen, fluoro, chloro, hydroxy, methyl or methoxy;

R^4 is hydrogen, methyl, or ethyl;

R^8 is hydrogen, fluoro, chloro, methyl or methoxy;

R^{10} is hydrogen, fluoro, chloro, hydroxy, methyl, methoxy, mono-, di- or tri-fluoro methyl, or mono-, di- or tri-fluoromethoxy; and

R^{10A} represents from 0 to 3 substituents independently selected from hydrogen, fluoro, chloro, hydroxy, methyl, methoxy, mono-, di- and tri-fluoromethyl, and mono-, di-, and tri-fluoromethoxy.

28. A compound or salt according to Claim 1, of Formula XI



Formula XI

wherein:

R represents from 0 to 4 substituents independently chosen from fluoro, chloro, hydroxy, C_1-C_6alkoxy, and C_1-C_6alkyl;

R^4 is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, fluoro, or chloro;

R^8 represents from 0 to 4 substituents independently chosen from C_1-C_6alkyl, C_1-C_6haloalkyl, fluoro, and chloro;

R^5 and R^6 are independently selected from hydrogen, fluoro, chloro, C_1-C_6alkyl, optionally substituted C_1-C_6alkoxy, and C_1-C_6haloalkyl;

R^7 is hydrogen or C_1-C_6alkyl;

R^{10} represents from 0 to 5 substituents independently chosen from fluoro, chloro, bromo, iodo, hydroxy, nitro, cyano, -COOH, carboxamide, dimethylcarboxamide, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy; and

Ar_1 is:

(i) phenyl optionally substituted with from 1 to 5 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, -COOH, carboxamide, C_1-C_3alkoxy, C_1-C_3alkyl, C_1-C_2haloalkyl, C_1-C_2alkoxycarbonyl, mono- and di-(C_1-C_2alkyl)amino, and C_1-C_2haloalkoxy;

(ii) naphthyl;

(iii) heterocyclic groups having 1 or 2 rings, 3 to 8 atoms in each ring and in at least one ring from 1 to 3 heteroatoms independently selected from N, O and S;

(iv) biphenyl; or

(v) phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having from 5 to 7 ring atoms, with 0, 1, or 2 ring atoms independently chosen from N, O and S, and with remaining ring atoms being carbon;

wherein each of (ii), (iii), (iv) and (v) is optionally substituted with from 1 to 4 substituents independently selected from halogen, hydroxy, C_1-C_2alkyl, C_1-C_2alkoxy, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

29. A compound according to Claim 1, which is:

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[8-methoxy-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-methyl-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-2-[1-ethyl-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)acetamide;

2-[1-(2,4-difluorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

N-(2-fluorobenzyl)-N-{3-[1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-3-oxopropyl}indan-2-amine;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

N-(indan-2-yl)-2-[1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(pyridin-2-ylmethyl)acetamide;

N-(indan-2-yl)-2-[1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(pyridin-3-ylmethyl)acetamide;

2-[1-(2-bromophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

N-(indan-2-yl)-2-[1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(1,3-thiazol-2-ylmethyl)acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-(2-methoxyphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-2-[1-(2,3-dimethylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1R)-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(4R)-4-methyl-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1S)-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-2-[1-(2-ethylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)acetamide;

N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(4-methyl-1-o-tolyl-3,4-dihydro-1H-isoquinolin-2-yl)-acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1R,4S)-4-methyl-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1S,4S)-4-methyl-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

2-{[1-(indan-2-yl)-2-phenyl-1H-imidazol-5-yl]methyl}-1-(2-methylphenyl)-1,2,3,4-tetrahydroisoquinoline;

(2S)-N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1R)-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

N-(indan-2-yl)-2-[1-(3,4-dimethylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)acetamide;

2-[1-(2,3-dichlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-[4-fluoro-2-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-[5-fluoro-2-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

(2S)-N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1S)-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

2-[(1S)-1-(2-bromophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1S)-1-[2-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

(2S)-N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1R)-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

2-[1-(1,1'-biphenyl-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-(1-naphthyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1R,4R)-4-methyl-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

2-[1-(2-chloro-3-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-(3-fluoro-2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-2-[1-(2,5-dimethylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-[3-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

2-[1-(5-chloro-2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

2-[1-(2-chloro-5-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

2-[1-(2,3-dihydro-1-benzofuran-7-yl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1R,4R)-1-(2-fluorophenyl)-4-methyl-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(3S)-3-methyl-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-2-[1-(2,6-dimethylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-(5-fluoro-2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1R)-1-(2-fluorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

2-[(1R,4R)-1-(2-chlorophenyl)-4-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

(2S)-N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1R)-1-(2-fluorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-(3-fluoro-4-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-(1-quinolin-8-yl-3,4-dihydroisoquinolin-2(1H)-yl)acetamide;

(2S)-N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1R)-1-(1-naphthyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)propanamide;

2-[1-(3-chloro-2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-(2-fluoro-5-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

(2S)-N-(indan-2-yl)-2-[(1R)-1-(2,3-dimethylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)propanamide;

(2S)-N-(indan-2-yl)-2-[(1S)-1-(2,3-dimethylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)propanamide;

(2S)-N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1R)-1-[2-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

(2S)-2-[(1R)-1-(2-bromophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)propanamide;

(2S)-N-(indan-2-yl)-2-[(1R)-1-(2,6-dimethylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)propanamide;

N-(indan-2-yl)-2-[6,7-dimethyl-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)acetamide;

N-(indan-2-yl)-2-[7,8-dimethyl-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)acetamide;

2-[1-(2,3-difluorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

(2S)-2-[(1R)-1-(2,3-dihydro-1-benzofuran-7-yl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)propanamide;

methyl 4-(2-{2-[indan-2-yl(2-fluorobenzyl)amino]-2-oxoethyl}-1,2,3,4-tetrahydroisoquinolin-1-yl)benzoate;

(2S)-N-benzyl-2-[(1R)-1-(2-bromophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-chloro-4-hydroxybenzyl)propanamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[8-methyl-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(3-methoxybenzyl)-2-[1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-(1-mesityl-3,4-dihydroisoquinolin-2(1H)-yl)acetamide;

2-[1-(2,6-difluorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

N-(2-fluorobenzyl)-2-[1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-phenylacetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-(2-methyl-1-naphthyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

(2S)-2-[(1R)-1-(2-chloro-5-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)propanamide;

(2S)-N-(indan-2-yl)-2-[(1S)-1-(2,5-dimethylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)propanamide;

(2S)-N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[(1R)-1-(2-fluoro-5-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N,N-bis(2-fluorobenzyl)propanamide;

4-[(indan-2-yl{[1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetyl}amino)methyl]benzoic acid;

(2S)-2-[(1R)-1-(2,6-difluorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-hydroxybenzyl)propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)-N-(2-phenylethyl)propanamide;

N-(indan-2-yl)-N-(3-hydroxybenzyl)-2-[1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

2-[1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)-N-(5-methoxy-indan-2-yl)acetamide;

N-(2-fluorobenzyl)-N-(5-methoxy-indan-2-yl)-2-[1-[2-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

2-[1-(2,6-dichlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

2-[1-(2-chloro-6-fluorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(1H-imidazol-4-ylmethyl)propanamide;

3-{[{(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanoyl}(indan-2-yl)amino]methyl}benzoic acid;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-[2-fluoro-6-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[8-fluoro-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

N-(indan-2-yl)-N-(2-fluoro-5-hydroxybenzyl)-2-[1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

(2S)-2-[(1R)-1-(2,6-dichlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)propanamide;

(2S)-2-[(1R)-1-(2-chloro-6-fluorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-[2-(2-fluorophenyl)ethyl]-N-(4-hydroxybenzyl)propanamide;

3-{[{(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanoyl}(indan-2-yl)amino]methyl}-N,N-dimethylbenzamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(4-hydroxy-3,5-dimethylbenzyl)propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-flurorobenzyl)propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-[2-(2-fluorophenyl)ethyl]-N-(2-phenylethyl)propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(2-fluorobenzyl)-N-[2-(2-fluorophenyl)ethyl]propanamide;

(2S)-2-[(1R)-1-(2,6-dichlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(4-hydroxy-3,5-dimethylbenzyl)propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(3-cyanobenzyl)-N-(indan-2-yl)propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(3-nitrobenzyl)propanamide;

N-(indan-2-yl)-N-(3-hydroxybenzyl)-2-[(1S)-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(3-hydroxybenzyl)propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluoro-3-hydroxybenzyl)propanamide;

2-[8-chloro-1-(2-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

2-[8-chloro-1-(2-chloro-6-fluorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-(indan-2-yl)-N-(2-fluorobenzyl)acetamide;

(2S)-N-(2-fluorobenzyl)-N-[2-(4-hydroxyphenyl)ethyl]-2-[(1R)-1-(1-naphthyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

(2S)-N-(2-fluorobenzyl)-N-[2-(1H-indol-3-yl)ethyl]-2-[(1R)-1-(1-naphthyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

(2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-[3-(difluoromethoxy)-2-fluorobenzyl]-N-(indan-2-yl)propanamide;

(2S)-N-(indan-2-yl)-N-[(2-methoxypyridin-3-yl)methyl]-2-[(1R)-1-(1-naphthyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

(2S)-N-(2-fluorobenzyl)-N-[(2-methoxypyridin-3-yl)methyl]-2-[(1R)-1-(1-naphthyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

N-(indan-2-yl)-N-(2-fluorobenzyl)-2-[1-(4-hydroxyphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetamide;

(2S)-N-(indan-2-yl)-N-[(6-methoxypyridin-2-yl)methyl]-2-[(1R)-1-(1-naphthyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

(2S)-N-(2-fluorobenzyl)-N-[(6-methoxypyridin-2-yl)methyl]-2-[(1R)-1-(1-naphthyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

(2S)-N-(indan-2-yl)-N-[(3-fluoropyridin-2-yl)methyl]-2-[(1R)-1-(1-naphthyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide;

(2S)-N-(indan-2-yl)-N-[(5-methoxypyridin-3-yl)methyl]-2-[(1R)-1-(1-naphthyl)-3,4-dihydroisoquinolin-2(1H)-yl]propanamide; or

a pharmaceutically acceptable salt thereof.

30. A compound or pharmaceutically acceptable salt according to Claim 1 which is



31. A compound of Formula XII



Formula XII

or a pharmaceutically acceptable salt thereof, wherein:

R represents from 0 to 4 substituents independently chosen from fluoro, chloro, hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy;

R^1 and Ar^2 are independently chosen from:

(i) phenyl(C_0-C_1alkyl), substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cyano, amino, nitro, -COOH, carboxamide, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6haloalkyl and C_1-C_6haloalkoxy; and

(ii) 2-indanyl, substituted with 0, 1 or 2 substituents independently selected from fluoro, chloro, hydroxy, methyl, ethyl, methoxy, ethoxy, mono-, di- and tri-fluoromethyl, and mono-, di- and tri-fluoromethoxy;

R^4 is C_1-C_6alkyl, C_1-C_2haloalkyl, fluoro or chloro;

R^7 is hydrogen or C_1-C_6alkyl;

R^9 represents from 0 to 5 substituents independently chosen from hydrogen, halogen, hydroxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy; and

┆ represents a single or double bond.

32. A compound according to claim 31, wherein the compound is:

N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl)-acetamide;

N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(2-o-tolyl-piperidin-1-yl)-acetamide;

N-(2-Fluoro-benzyl)-N-indan-2-yl-2-[2-(2-methoxy-phenyl)-piperidin-1-yl]-acetamide;

N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(2-o-tolyl-piperidin-1-yl)-propionamide.

2-(4,5-Dimethyl-6-phenyl-3,6-dihydro-2H-pyridin-1-yl)-N-(2-fluoro-benzyl)-N-indan-2-yl-acetamide;

2-(4,5-Dimethyl-6-o-tolyl-3,6-dihydro-2H-pyridin-1-yl)-N-(2-fluoro-benzyl)-N-indan-2-yl-acetamide;

or a pharmaceutically acceptable salt thereof.

33. A compound of Formula XIII



Formula XIII

or a pharmaceutically acceptable salt thereof, wherein:

R^1 and Ar^2 are independently chosen from:

(i) phenyl(C_0-C_1alkyl), substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cyano, amino, nitro, -COOH, carboxamide, mono- and di-(C_1-C_6alkyl) amino, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy; and

(ii) 2-indanyl, substituted with 0, 1 or 2 substituents independently selected from fluoro, chloro, hydroxy, methyl, ethyl, methoxy, ethoxy, mono-, di- and tri-fluoromethyl, and mono-, di- and tri-fluoromethoxy;

R^4 is C_1-C_6alkyl, haloC_1-C_6alkyl, fluoro or chloro;

R^3 and R^7 are independently hydrogen or C_1-C_6alkyl; and

R^9 and R^{10} independently represent from 0 to 5 substituents independently chosen from hydrogen, halogen, hydroxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy.

34. A compound according to claim 33, wherein the compound is (Benzhydryl-methyl-amino)-N-(2-fluoro-benzyl)-N-indan-2-yl-acetamide.

35. A compound of Formula XIV



Formula XIV

or a pharmaceutically acceptable salt thereof, wherein:

R represents from 0 to 2 substituents independently chosen from fluoro, chloro, hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl, C_1-C_2alkyl, and C_1-C_2alkoxy;

R^1 and Ar^2 are independently chosen from:

(i) phenyl(C_0-C_1alkyl), substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cyano, amino, nitro, -COOH, carboxamide, mono- and di-(C_1-C_6alkyl) amino, haloC_1-C_6alkyl and haloC_1-C_6alkoxy; and

(ii) 2-indanyl, substituted with 0, 1 or 2 substituents independently selected from fluoro, chloro, hydroxy, methyl, ethyl, methoxy, ethoxy, mono-, di- and tri-fluoromethyl, and mono-, di- and tri-fluoromethoxy;

R^4 is C_1-C_6alkyl, haloC_1-C_6alkyl, fluoro or chloro;

R^7 is hydrogen or C_1-C_6alkyl; and

R^9 represents from 0 to 5 substituents independently chosen from hydrogen, halogen, hydroxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy.

36. A compound according to Claim 34, wherein the compound is N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(4-o-tolyl-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-acetamide.

37 A compound of or salt Claim 1, having a enantiomeric excess of at least 90%.

38. A pharmaceutical composition comprising at least one compound or salt according to Claim 1, or a prodrug or hydrate thereof, in combination with a physiologically acceptable carrier or excipient.

39. A compound or salt according to Claim 1, wherein the compound exhibits an IC_{50} of 100 nM or less in a standard *in vitro* C5a receptor-mediated chemotaxis or calcium mobilization assay.

40. A compound or salt according to Claim 1, wherein the compound exhibits less than 5% agonist activity in a GTP binding assay.

41. A method for inhibiting signal-transducing activity of a cellular C5a receptor, comprising contacting a cell expressing a C5a receptor with at least one compound or salt according to Claim 1, and thereby reducing signal transduction by the C5a receptor.

42. A method according to Claim 41, wherein the cell is contacted *in vivo* in an animal.

43. A method according to Claim 42, wherein the animal is a human.

44. A method of inhibiting binding of C5a to C5a receptor *in vitro*, the method comprising contacting C5a receptor with at least one compound or salt according to Claim 1, under conditions and in an amount sufficient to detectably inhibit C5a binding to C5a receptor.

45. A method of inhibiting binding of C5a to C5a receptor in a human patient, comprising contacting cells expressing C5a receptor with at least one compound or salt according to Claim 1, in an amount sufficient to detectably inhibit C5a binding to cells expressing a cloned C5a receptor *in vitro*, and thereby inhibiting binding of C5a to the C5a receptor in the patient.

46. A method for treating a patient suffering from rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, or bronchial asthma comprising administering to the patient a C5a receptor modulatory amount of a compound according to Claim 1.

47. A method for treating a patient suffering from stroke, myocardial infarction, atherosclerosis, ischemic heart disease, or ischemia-reperfusion injury comprising administering to the patient a C5a receptor modulatory amount of a compound according to Claim 1.

48. A method for inhibiting C5a receptor-mediated cellular chemotaxis, comprising contacting mammalian white blood cells with a C5a receptor modulatory amount of a compound or salt according to Claim 1.

49. A method for localizing C5a receptors in a tissue sample, comprising:

contacting the tissue sample containing C5a receptors with a detectably labeled compound according to Claim 1 under conditions that permit binding of the compound to C5a receptors; and

detecting the bound compound.

50. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to Claim 38 in a container; and

(b) instructions for using the composition to treat a patient suffering from rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, or bronchial asthma.

51. A packaged pharmaceutical preparation

(a) a pharmaceutical composition according to Claim 38 in a container; and

(b) instructions for using the composition to treat stroke, myocardial infarction, atherosclerosis, ischemic heart disease, or ischemia-reperfusion injury.

52. A pharmaceutical composition according to Claim 38, wherein the pharmaceutical composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup, or a transdermal patch.